[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100484586":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":23,"centralContacts":27,"locations":32,"responsibleParty":53,"collaborators":10,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":59,"acronym":10,"eligibilityCriteria":60,"healthyVolunteers":57,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":10,"studyType":67,"phases":10,"briefSummary":68,"conditions":69,"keywords":10,"overallStatus":35,"whyStopped":10,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Helse Stavanger HF","OTHER_GOV",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Acute",null,"Patients with acute first attack CSC with subretinal fluid (SRF) on OCT and symptom duration under 4 months.",{"label":13,"type":10,"description":14,"interventionNames":15},"Chronic","Patients with chronic CSC, i.e. symptoms and SRF for more than 4 months.",[16],"Drug: Verteporfin",[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"DRUG","Verteporfin","Chronic CSC are receiving one treatment before the observation period.",[13],[24],{"name":25,"affiliation":5,"role":26},"Vegard Forsaa, MD PhD","PRINCIPAL_INVESTIGATOR",[28],{"name":25,"role":29,"phone":30,"phoneExt":10,"email":31},"CONTACT","+4748152212","forsaa@gmail.com",[33],{"facility":34,"status":35,"city":36,"state":10,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Stavanger University Hospital, Department of Ophthalmology","RECRUITING","Stavanger","4016","Norway","NO",{"type":41,"coordinates":42},"Point",[43,44],5.73332,58.97005,{"lat":44,"lon":43},[47,51],{"name":48,"role":29,"phone":49,"phoneExt":10,"email":50},"Vegard Forsaa, MD","+47 48152212","vegard.forsaa@sus.no",{"name":52,"role":26,"phone":10,"phoneExt":10,"email":10},"Vegard Forsaa, PhD",{"type":54,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100484586","choroidal-blood-flow-in-acute-and-chronic-central-serous-chorioretinopathy-100484586",false,"NCT05589974","Choroidal Blood Flow in Acute and Chronic Central Serous Chorioretinopathy","Inclusion Criteria:-\n\n* Able to sign informed consent\n* Possible to obtain fundus imaging\n* Acute CSC ˂4 months of duration in one eye, defined as:\n\n  1. Subfoveal presence of SRF on OCT\n  2. Present attack is 1st -3rd attack of CSC\n\n  b) Patient history and examination consistent with acute CSC c) Characteristic appearance of acute CSC on fundus autofluorescence (FAF) and OCT\n* Chronic CSC ≥4 months of duration in one eye, defined as:\n\n  1. Subfoveal presence of SRF on OCT\n  2. Subjective visual loss\u002Fsymptoms\n  3. Characteristic appearance of chronic CSC on FAF, fluorescein angiography (FA), and indocyanin angiography (ICGA) and OCT\n  4. Patient history and examination consistent with chronic CSC\n\nExclusion Criteria:\n\n* History of retinal disease other than CSC (e.g. retinal detachment)\n* Contraindications for FA, ICGA or PDT (only for chronic CSC)","ALL","18 Years","70 Years",{"count":65,"type":66},50,"ESTIMATED","OBSERVATIONAL","Patients with central serous chorioretinopathy (CSC) will be monitored with laser speckle flow graphy (LSFG), swept source optical coherence tomography (SS-OCT) and SS-OCT angiography (SS-OCTA). The aim is to unveil the flow and pulse wave characteristics of the choroidal circulation in acute CSC and chronic CSC.",[70],"Central Serous Chorioretinopathy","2024-03-14",{"date":73,"type":74},"2024-03-18","ACTUAL",{"date":76,"type":74},"2022-10-01",{"date":78,"type":66},"2026-07-31",{"name":5,"class":6},1]